-
EP4375295
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4375295
| EP4375295 - ANTIBODY DRUG FOR PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 27.04.2024 Database last updated on 15.08.2024 | |
| Former | The international publication has been made Status updated on 03.03.2023 | Most recent event Tooltip | 27.04.2024 | Publication in section I.1 EP Bulletin | published on 29.05.2024 [2024/22] | 27.04.2024 | Request for examination filed | published on 29.05.2024 [2024/22] | Applicant(s) | For all designated states Immunemed Inc. 2-2 32 Soyanggang-ro Chuncheon-si Gangwon-do 24232 / KR | [2024/22] | Inventor(s) | 01 /
CHO, Mi-La Seoul 04427 / KR | 02 /
LEE, Seon-Yeong Seoul 07766 / KR | 03 /
LEE, Aram Jinju-si Gyeongsangnam-do 52835 / KR | 04 /
CHOI, Jeong-Won Seoul 02160 / KR | 05 /
KIM, Yoon-Won Chuncheon-si Gangwon-do 24414 / KR | 06 /
PARK, Sungman Chuncheon-si Gangwon-do 24290 / KR | 07 /
LEE, Byung-Cheol Chuncheon-si Gangwon-do 24279 / KR | 08 /
LEE, Ah-Lum Uijeongbu-si Gyeonggi-do 11793 / KR | [2024/22] | Representative(s) | Isarpatent Patent- und Rechtsanwälte Barth Hassa Peckmann & Partner mbB Friedrichstraße 31 80801 München / DE | [2024/22] | Application number, filing date | 22861715.5 | 24.08.2022 | [2024/22] | WO2022KR12660 | Priority number, date | KR20210113361 | 26.08.2021 Original published format: KR 20210113361 | [2024/22] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2023027507 | Date: | 02.03.2023 | Language: | KO | [2023/09] | Type: | A1 Application with search report | No.: | EP4375295 | Date: | 29.05.2024 | Language: | EN | [2024/22] | Search report(s) | International search report - published on: | KR | 02.03.2023 | Classification | IPC: | C07K16/18, A61P37/00, A61P19/02, G01N33/68, A61K39/00 | [2024/22] | CPC: |
A61P19/02 (EP);
A61P37/00 (EP);
C07K16/18 (EP);
G01N33/564 (EP);
A61K2039/505 (EP);
C07K2317/76 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/22] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | ANTIKÖRPERARZNEIMITTEL ZUR PRÄVENTION ODER BEHANDLUNG VON AUTOIMMUNERKRANKUNGEN | [2024/22] | English: | ANTIBODY DRUG FOR PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES | [2024/22] | French: | MÉDICAMENT À BASE D'ANTICORPS POUR LA PRÉVENTION OU LE TRAITEMENT DE MALADIES AUTO-IMMUNES | [2024/22] | Entry into regional phase | 23.02.2024 | Translation filed | 23.02.2024 | National basic fee paid | 23.02.2024 | Search fee paid | 23.02.2024 | Designation fee(s) paid | 23.02.2024 | Examination fee paid | Examination procedure | 23.02.2024 | Examination requested [2024/22] | 27.02.2024 | Amendment by applicant (claims and/or description) |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2015010791 (KLARESKOG LARS [SE], et al); | [XY]US2015056208 (KLARESKOG LARS [SE], et al); | [Y]KR101912375B ; | [A]KR20210049871 (REGENERON PHARMA [US], et al); | [A]KR20210058723 (CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION [KR]) | by applicant | WO9413804 | KR20210083361 | WO1992US09965 |